Multiple Endocrine Neoplasia: Clinical Trials

25 completed. 25 Phase 1, 3 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	25	Completed 25
Phase 2	3	Completed 3

Follow Multiple Endocrine Neoplasia: new trials by email Literature Review of Multiple Endocrine Neoplasia trials Research Report on Multiple Endocrine Neoplasia

Trials (filtered) newest first · largest first

All 25 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy Women Elinzanetant (BAY3427080), Placebo to elinzanetant, Zopiclone - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes	Phase 1	Completed	Bayer	64	2024-01-08	2024-05-08
A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants Moxifloxacin, Elinzanetant (BAY3427080), Placebo - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes	Phase 1	Completed	Bayer	51	2022-08-19	2023-05-09
A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants Elinzanetant (BAY3427080), Dabigatran etexilate - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes	Phase 1	Completed	Bayer	20	2022-08-05	2022-11-22
A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years Elinzanetant (BAY3427080), Placebo - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes	Phase 1	Completed	Bayer	16	2022-05-23	2022-07-27
A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants Elinzanetant (BAY3427080) - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes	Phase 1	Completed	Bayer	18	2022-05-04	2022-07-19
A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally Elinzanetant (BAY3427080) - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men	Phase 1	Completed	Bayer	31	2021-10-14	2025-07-14
A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults Elinzanetant (BAY3427080), Esomeprazole - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes	Phase 1	Completed	Bayer	14	2021-09-30	2022-03-17
A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years. Elinzanetant (BAY3427080), Midazolam, Carbamazepine - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men	Phase 1	Completed	Bayer	16	2021-09-06	2022-02-25
A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults Elinzanetant (BAY3427080), Placebo - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men	Phase 1	Completed	Bayer	62	2021-08-11	2022-03-29
A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants BAY3427080 - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men	Phase 1	Completed	Bayer	33	2021-06-01	2022-03-24
A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy Participants Elinzanetant (BAY3427080), Rosuvastatin - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men	Phase 1	Completed	Bayer	16	2021-05-26	2023-08-09
Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body Elinzanetant (BAY3427080) treatment A, Elinzanetant (BAY3427080) treatment B - Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men	Phase 1	Completed	Bayer	16	2021-04-09	2023-08-09
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women Blueberry Powder, Placebo Powder - Hypertension, Aging	Phase 1 / Phase 2	Completed	Colorado State University	60	2020-01-01	2026-10-30
Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors BOS172738 - Advanced Nonhaematologic Malignancies	Phase 1	Completed	Boston Pharmaceuticals	117	2018-12-12	2023-10-30
Impact of Acetazolamide in Reducing Referred Postoperative Pain Acetazolamide, Placebo - Prostate Cancer, Men	Phase 1	Completed	Medical College of Wisconsin	33	2018-08-22	2022-09-23
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers GSK3352589, Matching Placebo - Irritable Bowel Syndrome	Phase 1	Completed	GlaxoSmithKline	68	2017-05-17	2019-08-09
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer	Phase 1 / Phase 2	Completed	Hoffmann-La Roche	590	2017-03-17	2025-05-31
Alcohol and Implicit Process in Sexual Risk Behavior in MSM Alcohol, Placebo (non-alcoholic beverage) - Alcohol Drinking, Sex Behavior	Phase 1	Completed	Syracuse University	260	2016-05-01	2021-07-23
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers GSK3179106, Placebo - Irritable Bowel Syndrome	Phase 1	Completed	GlaxoSmithKline	16	2015-11-26	2017-05-08
The Effect of a High-dose Oral Vitamin D3 Bolus on Serum 25(OH)D3 and Vitamin D Receptor Target Gene Expression Vitamin D3, Placebo - Vitamin D Receptor Target Gene Expression, Serum 25(OH)D Concentration	Phase 1	Completed	University of Eastern Finland	35	2014-02-01	2016-07-29

Showing 20 of 25. Sign in to see all of them.

Narrower conditions

Multiple Endocrine Neoplasia Type 1 (20)  ·  Hot Flashes (7)  ·  Multiple Endocrine Neoplasia Type 2a (5)  ·  Carcinoma, Medullary (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Irritable Bowel Syndrome (2)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma, Papillary (1)  ·  Alcohol Drinking (1)  ·  Atherosclerosis (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Bronchogenic (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Cardiovascular Diseases (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (25)  ·  Genetic Diseases, Inborn (25)  ·  Neoplasms, Multiple Primary (25)  ·  Neoplastic Syndromes, Hereditary (25)  ·  Endocrine Gland Neoplasms (24)  ·  Endocrine System Diseases (24)  ·  Neoplasms (24)  ·  Neoplasms by Site (24)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Signs and Symptoms (10)  ·  Neoplasms, Ductal, Lobular, and Medullary (3)  ·  Neurologic Manifestations (3)  ·  Adenocarcinoma (2)  ·  Carcinoma (2)

Interventions

Acetazolamide (1)  ·  Carbamazepine (1)  ·  Cholecalciferol (1)  ·  Dabigatran (1)  ·  Esomeprazole (1)  ·  Ethanol (1)  ·  GSK3352589 (1)  ·  Methylphenidate (1)  ·  Midazolam (1)  ·  Moxifloxacin (1)  ·  N-((1-((5-(4-fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide (1)  ·  Rosuvastatin Calcium (1)  ·  pralsetinib (1)  ·  vandetanib (1)  ·  zopiclone (1)

Sponsors

Bayer (12)  ·  GlaxoSmithKline (4)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2)  ·  Boston Pharmaceuticals (1)  ·  Colorado State University (1)  ·  Hoffmann-La Roche (1)  ·  Medical College of Wisconsin (1)  ·  National Cancer Institute (NCI) (1)  ·  Syracuse University (1)  ·  University of Eastern Finland (1)

Countries

United States (10)  ·  Germany (8)  ·  Australia (2)  ·  Belgium (2)  ·  China (2)  ·  France (2)  ·  Hong Kong (2)  ·  Netherlands (2)  ·  South Korea (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Canada (1)  ·  Finland (1)  ·  Italy (1)  ·  Japan (1)

Top investigators

Brigitte C Widemann, M.D. (1)  ·  Jeffrey Simons, PhD (1)  ·  Jyrki K Virtanen, PhD (1)  ·  Scott Johnson, MD (1)  ·  Steve A Maisto, PhD (1)  ·  Tibor P.A. Palfai, PhD (1)

Results publications

PMID 23766359, PMID 24617713, PMID 25578927, PMID 25972901, PMID 27282116, PMID 29187393, PMID 30277655, PMID 33606922, PMID 34118197, PMID 34118198, PMID 35715405, PMID 35962206, PMID 37282666, PMID 37916501, PMID 37934000, PMID 38009200, PMID 40569207, PMID 40639400, PMID 41886723

NIH funding

2016 (1), 2018 (1), R01AA022301 (1)